| Literature DB >> 29100957 |
Sergey G Klochkov1, Margarita E Neganova1, Nagendra Sastry Yarla2, Madhukiran Parvathaneni3, Bechan Sharma4, Vadim V Tarasov5, George Barreto6, Sergey O Bachurin1, Ghulam Md Ashraf7, Gjumrakch Aliev8.
Abstract
Ras proteins have been reported to play key role in oncologic diseases. Ras proteins are associated with cellular membranes for its carcinogenic activities through post-translational modifications, including farnesylation. Farnesyltransferase is responsible for a type of Ras membrane targeting, which leads to cancer origin and progression. Inhibitors of farnesyltransferase have been developed as novel anticancer agents. In this review, the role of farnesyltransferase in cancer progression and development has been discussed. Further, the current status of development of farnesyltransferase inhibitors for cancer prevention and treatment has also been reviewed.Entities:
Keywords: Cancer; Farnesyltransferase; Farnesyltransferase inhibitor; Ras protein; Therapy
Mesh:
Substances:
Year: 2017 PMID: 29100957 DOI: 10.1016/j.semcancer.2017.10.010
Source DB: PubMed Journal: Semin Cancer Biol ISSN: 1044-579X Impact factor: 15.707